A constituent of cannabis known as Cannabidiol could hold promise as a new class of treatment for psychosis, according to King’s College London research showing significant benefits in a clinical trial. The main psychoactive compound in cannabis is delta-9-tetrahydrocannabinol (THC), which is responsible for many of the drug’s harmful effects, such as paranoia and anxiety. However, previous research at King’s College London has shown that its second major constituent, cannabidiol (CBD), has broadly opposite effects to THC, suggesting that it might be useful as a treatment in mental health. To date, a few case studies have pointed to the potential

The post Cannabidiol could Treat Psychosis appeared first on The Hippocratic Post.